430 related articles for article (PubMed ID: 27040815)
1. A small molecule nanodrug consisting of amphiphilic targeting ligand-chemotherapy drug conjugate for targeted cancer therapy.
Mou Q; Ma Y; Zhu X; Yan D
J Control Release; 2016 May; 230():34-44. PubMed ID: 27040815
[TBL] [Abstract][Full Text] [Related]
2. Fullerene (C60)-based tumor-targeting nanoparticles with "off-on" state for enhanced treatment of cancer.
Shi J; Wang B; Wang L; Lu T; Fu Y; Zhang H; Zhang Z
J Control Release; 2016 Aug; 235():245-258. PubMed ID: 27276066
[TBL] [Abstract][Full Text] [Related]
3. A novel high drug loading mussel-inspired polydopamine hybrid nanoparticle as a pH-sensitive vehicle for drug delivery.
Hou J; Guo C; Shi Y; Liu E; Dong W; Yu B; Liu S; Gong J
Int J Pharm; 2017 Nov; 533(1):73-83. PubMed ID: 28943209
[TBL] [Abstract][Full Text] [Related]
4. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy.
Xia Y; Xu T; Wang C; Li Y; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():143-159. PubMed ID: 29317822
[TBL] [Abstract][Full Text] [Related]
5. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
[TBL] [Abstract][Full Text] [Related]
6. Surface-Modified Nanoerythrocyte Loading DOX for Targeted Liver Cancer Chemotherapy.
Wang Y; Chen X; He D; Zhou Y; Qin L
Mol Pharm; 2018 Dec; 15(12):5728-5740. PubMed ID: 30359027
[TBL] [Abstract][Full Text] [Related]
7. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin.
Chen WL; Li F; Tang Y; Yang SD; Li JZ; Yuan ZQ; Liu Y; Zhou XF; Liu C; Zhang XN
Int J Nanomedicine; 2017; 12():4241-4256. PubMed ID: 28652730
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
10. Self-crosslinkable and intracellularly decrosslinkable biodegradable micellar nanoparticles: A robust, simple and multifunctional nanoplatform for high-efficiency targeted cancer chemotherapy.
Zou Y; Fang Y; Meng H; Meng F; Deng C; Zhang J; Zhong Z
J Control Release; 2016 Dec; 244(Pt B):326-335. PubMed ID: 27245309
[TBL] [Abstract][Full Text] [Related]
11. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery.
Bao Y; Yin M; Hu X; Zhuang X; Sun Y; Guo Y; Tan S; Zhang Z
J Control Release; 2016 Aug; 235():182-194. PubMed ID: 27264552
[TBL] [Abstract][Full Text] [Related]
12. Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy.
Han HS; Choi KY; Ko H; Jeon J; Saravanakumar G; Suh YD; Lee DS; Park JH
J Control Release; 2015 Feb; 200():158-66. PubMed ID: 25550153
[TBL] [Abstract][Full Text] [Related]
13. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
[TBL] [Abstract][Full Text] [Related]
14. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
Du H; Liu M; Yu A; Ji J; Zhai G
Int J Pharm; 2017 May; 523(1):427-438. PubMed ID: 28359815
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy.
Khaliq NU; Sandra FC; Park DY; Lee JY; Oh KS; Kim D; Byun Y; Kim IS; Kwon IC; Kim SY; Yuk SH
Biomaterials; 2016 Sep; 101():131-42. PubMed ID: 27286189
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional hollow nanoparticles based on graft-diblock copolymers for doxorubicin delivery.
Lu PL; Chen YC; Ou TW; Chen HH; Tsai HC; Wen CJ; Lo CL; Wey SP; Lin KJ; Yen TC; Hsiue GH
Biomaterials; 2011 Mar; 32(8):2213-21. PubMed ID: 21176954
[TBL] [Abstract][Full Text] [Related]
18. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-Bound Hydroxyethyl Starch Conjugate Nanoparticles with pH/Redox Responsive Linkage for Enhancing Antitumor Therapy.
Tan R; Tian D; Liu J; Wang C; Wan Y
Int J Nanomedicine; 2021; 16():4527-4544. PubMed ID: 34276212
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]